Nanomedicine. 2014;9(1):105-120. Overall, HDL-based siRNA delivery possesses many attractive features, including ultra-small size, favorable surface properties (no PEGylation is required for achieving ...

• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreement with AstraZeneca, a global ...

In a study published in Cell Reports Physical Science on Nov. 25, a research team led by Prof. CAI Lintao from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences ...

A study published in the Journal of Controlled Release ("NMR-based analysis of impact of siRNA mixing conditions on internal structure of siRNA-loaded LNP"), led by Assistant Professor Keisuke Ueda ...

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...

In a new study published in the Clinical and Translational Medicine, the research group of Prof. Chen-Yu Zhang and Prof. Xi Chen at Nanjing University evaluated the on- and off-target effects of ...

In Parkinson’s disease, α-synuclein accumulates in neurons and may thereby contribute to their degeneration. Reducing expression of α-synuclein may be an effective therapy, but delivering short ...

TAMs are crucial immune cells in the tumor microenvironment and key targets for tumor immunotherapy, with gene therapy being an important approach. However, existing gene carriers are unsatisfactory ...

Table 2. Stable nucleic acid lipid particle formulations. Stable nucleic acid lipid particle formulations in systemic delivery Target siRNA and modification (yes/no) Animal model Ref.